ArticleCancers2024

Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival.

Andrea Ossato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.